Antigua and Barbuda vs Lebanon: Prevalence rate of hypertension in men aged 30-79
Antigua and Barbuda
41.9
in 2019
Lebanon
42.1
in 2019
Antigua and Barbuda rank
56th
Lebanon rank
55th
Prevalence rate of hypertension in men aged 30-79 over time
- Antigua and Barbuda
- Lebanon
How they compare
Lebanon currently reports 42.1 against 41.9 in Antigua and Barbuda, a difference of 0.2.
Across all 30 years both countries report, Lebanon has been ahead every year.
Antigua and Barbuda ranks 56th and Lebanon ranks 55th of 195 countries.
Lebanon has averaged higher in every one of the 3 decades both report.
Head to head by decade
| Decade | Antigua and Barbuda | Lebanon | Difference | Ahead |
|---|---|---|---|---|
| 1990s | 37.74 | 40.24 | 2.5 | Lebanon |
| 2000s | 40.36 | 42.16 | 1.8 | Lebanon |
| 2010s | 41.78 | 42.29 | 0.51 | Lebanon |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher prevalence rate of hypertension in men aged 30-79, Antigua and Barbuda or Lebanon?
- Lebanon, at 42.1 against 41.9 in Antigua and Barbuda as of 2019.
- What is the difference in prevalence rate of hypertension in men aged 30-79 between Antigua and Barbuda and Lebanon?
- 0.2, with Lebanon ahead.
- How many years of comparable data are there for Antigua and Barbuda and Lebanon?
- 30 years are reported by both, from 1990 to 2019.
- How do Antigua and Barbuda and Lebanon rank globally for prevalence rate of hypertension in men aged 30-79?
- Antigua and Barbuda ranks 56th and Lebanon ranks 55th of 195 countries.
- Where does this data come from?
- World Health Organization - Global Health Observatory (2026) – with minor processing by Our World in Data, published as Prevalence rate of hypertension in men aged 30-79. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Estimated share of male population with hypertension, based on population representative surveys and statistical modeling. Hypertension is a risk factor for chronic complications, including cardiovascular disease, and premature death.